Theory Paper IDrNB Cardiology – Theory Notes
POLYGENIC RISK SCORES (PRS) IN CARDIOVASCULAR DISEASE PREDICTION
ITHE CONCEPTUAL RATIONALE: MONOGENIC VS. POLYGENIC ARCHITECTURE
- The Monogenic Limitation: Rare, high-penetrance monogenic mutations—such as pathogenic variants in LDLR, APOB, or PCSK9 causing Familial Hypercholesterolemia (FH) (prevalence ~1 in 250 to 310)—confer a 3- to 4-fold increased risk of premature Coronary Artery Disease (CAD), but are identified in less than 2 to 5 percent of patients presenting with early-onset myocardial infarction.
- The Polygenic Reality (Khera et al., Nature Genetics 2018): In the vast majority of individuals, inherited susceptibility to CAD (as well as Atrial Fibrillation, Hypertension, and Type 2 Diabetes) is driven by the additive cumulative burden of thousands to millions of common Single Nucleotide Polymorphisms (SNPs) distributed across the genome. While any single common SNP exerts a tiny effect size (odds ratio 1.02 to 1.15), their aggregated genome-wide sum produces a wide Gaussian distribution of lifetime genetic risk.
- Mathematical Construction of a Genome-Wide Polygenic Risk Score (GPS / PRS): Calculated as the weighted sum of risk-associated alleles carried by an individual across M genetic variants (PRS = Sum of [Beta_i x Dosage_i]), where Beta_i is the log-odds effect weight derived from large discovery Genome-Wide Association Studies (GWAS) (e.g., CARDIoGRAMplusC4D, Million Veteran Program, UK Biobank) using linkage-disequilibrium clumping or Bayesian shrinkage algorithms (LDpred, PRS-CS).
IICLINICAL APPLICATION: THE “LIFETIME RISK-ENHANCING” PARADIGM
- Capture at Birth (Primordial and Early Primary Prevention): Because germline DNA does not change over a lifetime, a Polygenic Risk Score can be calculated from birth or young adulthood (age 20 to 40 years)—decades before age-dependent clinical calculators (such as the 10-year Pooled Cohort Equations, SCORE2, or PREVENT) cross treatment thresholds.
- The “Polygenic FH Equivalent” (Khera et al., Nature Genetics 2018): In the UK Biobank (n = 288,978), individuals in the top 8 percent (and especially the top 5 percent) of the genome-wide CAD Polygenic Risk Score distribution carry a 3-fold or greater increased risk of CAD—a risk magnitude identical to carrying a monogenic Familial Hypercholesterolemia mutation, yet 15 to 20 times more prevalent in the general population (80 per 1,000 vs. 4 per 1,000 for monogenic FH). Crucially, unlike monogenic FH (which is flagged by LDL-C >190 mg/dL), individuals with a high polygenic CAD score often have normal or borderline lipid and blood pressure levels, rendering them invisible to standard clinical screening.
- Interaction with Monogenic Mutations: Even among patients who carry a pathogenic monogenic FH (LDLR) or HCM/Brugada/LQTS variant, the background Polygenic Risk Score acts as a potent genetic modifier that explains incomplete penetrance and variable expressivity (e.g., why one family member with an LDLR mutation suffers an MI at age 35 while a sibling with the same mutation remains event-free at age 65).
IIILANDMARK CLINICAL EVIDENCE MATRIX
| Clinical Utility Domain | Landmark Study / Trial Substudy | Key Quantitative Finding & Clinical Implication |
|---|---|---|
| Polygenic “FH Equivalent” Identification | Khera et al. (Nature Genetics 2018; UK Biobank) | Top 8% of CAD PRS confers >=3-fold CAD risk (same as monogenic FH, but 20x more common and not identifiable by LDL-C alone) |
| Lifestyle Offsets Genetic Risk | Khera et al. (NEJM 2016 — “Genetics vs. Lifestyle”) | Among patients in the highest genetic risk quintile, adherence to a favorable lifestyle (no smoking, BMI <30, physical activity, healthy diet) reduced 10-year incident CAD events by 46% (“Genetics load the gun, lifestyle pulls the trigger”) |
| Superior Benefit from Statins & PCSK9 Inhibitors | WOSCOPS / JUPITER / ASCOT (Statins) & FOURIER / ODYSSEY OUTCOMES (Circulation 2020 — Evolocumab / Alirocumab) | Patients in the highest PRS tier derive a markedly greater relative and absolute risk reduction from Statins (nearly double the relative risk reduction of lower-risk tiers) and PCSK9 inhibitors (37% RRR in high PRS without clinical risk factors; NNT halved) |
| Integration with Coronary Artery Calcium (CAC) | MESA & Rotterdam Study Cohorts (JAMA 2023) | CAC remains superior to PRS in older adults (>55 yr), whereas PRS adds strongest reclassification in younger adults (<45–50 yr) before macroscopic calcification develops |
IVCURRENT GUIDELINE STATUS (ESC 2021 PREVENTION / ESC 2023 CARDIOMYOPATHY / AHA SCIENTIFIC STATEMENT 2022)
- General Population Screening (Class III — Not Recommended): The 2021 ESC Guidelines on Cardiovascular Disease Prevention do not recommend routine genetic or polygenic risk scoring in the general population (Class III, Level B) due to modest incremental C-statistic improvement (+0.01 to +0.03) when added to SCORE2 in middle-aged/older cohorts and lack of dedicated randomized clinical trial outcome data.
- Targeted Clinical Scenarios (AHA 2022 Scientific Statement on PRS / Selective Risk Enhancer):
- Borderline or Intermediate 10-Year ASCVD Risk (5% to 20%): A high CAD PRS (>=80th to 95th percentile) acts as a risk-enhancing factor that reclassifies 10 to 15 percent of intermediate-risk adults upward to favor early statin initiation.
- Young Adults (<40 to 45 Years) with Premature Family History: Identifies lifetime genetic vulnerability before CAC becomes positive (>0), guiding early intensive LDL-C/ApoB lowering.
- Secondary Prevention Intensification: Identifies post-ACS patients in the top PRS decile who derive the greatest absolute MACE reduction from PCSK9 inhibition (FOURIER / ODYSSEY OUTCOMES genetic substudies).
VLIMITATIONS AND THE “EUROCENTRIC DIVERSITY TRAP”
- Ancestral Transferability Bias: Historically, 75 to 85 percent of GWAS discovery cohorts were of European ancestry. Because allele frequencies, linkage disequilibrium (LD) block structures, and causal effect sizes differ across ancestral groups, European-derived PRSs show significantly degraded predictive accuracy (by 30 to 70 percent in African ancestry and 15 to 30 percent in South Asian ancestry) unless calibrated using multi-ancestry models.
- Non-Genetic Determinants: A PRS captures only common germline additive variance (heritability of CAD is ~40 to 50 percent); it does not capture somatic clonal hematopoiesis (CHIP — TET2, DNMT3A, ASXL1, JAK2), epigenetic modifications, or acute environmental triggers.
VIPRACTICAL APPLICATION IN THE INDIAN CLINICAL CONTEXT
- South Asian Multi-Ancestry PRS Development (Wang & Khera et al., JACC 2020; Patel et al., Nature Medicine 2023; GenomeIndia Project): Dedicated South Asian-calibrated Genome-Wide Polygenic Scores (validated in Indian case-control cohorts, PROMIS, and UK Biobank South Asians) demonstrate an odds ratio of 1.6 to 1.7 per standard deviation and identify the top 5 percent of Indians who carry a >3- to 4-fold risk of premature Myocardial Infarction.
- Highest Clinical Yield in India: In Indian preventive cardiology clinics, combining a South Asian-calibrated PRS with Lipoprotein(a) and Apolipoprotein B in young adults (aged 20 to 45 years) with a family history of premature CAD identifies high-risk individuals during the “CAC-zero window” (when non-calcified lipid-rich soft plaque is forming), justifying early lifestyle intervention and statin therapy.
Key references
- Khera AV, Chaffin M, Aragam KG, et al.: Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations, Nature Genetics, 2018.
- Khera AV, Emdin CA, Drake I, et al.: Genetic Risk, Adherence to a Healthy Lifestyle, and Coronary Disease, New England Journal of Medicine, 2016.
- O’Sullivan JW, Raghavan S, Marquez-Luna C, et al.: Polygenic Risk Scores for Cardiovascular Disease: A Scientific Statement From the American Heart Association, Circulation, 2022.
- Marston NA, Kamanu FK, Nordio F, et al. (FOURIER Investigators): Predicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease Using a Genetic Risk Score, Circulation, 2020.
meritmedscript.comDr. Sidhartha Mullapudi
